在患有HFrEF和HFmrEF/HFpEF的患者中使用EuroQol5维3级问卷水平总分 (EQ-5D-3L-LSS) 评估萨库比特里尔/瓦尔萨坦和生活质量
在PubMed上查看摘要
概括
此摘要是机器生成的。在心力衰竭 (HF) 患者中,萨库比特里尔/ 瓦尔萨坦改善了健康状况,并减少了心力衰竭事件. 通过EQ-5D-3L水平总分 (LSS) 测量,该疗法在所有严重程度上都显示出好处.
科学领域
- 心血管医学
- 健康经济学
- 药理学
背景情况
- EQ-5D-3L水平总分 (LSS) 是心力衰竭患者健康状况的衡量标准.
- 了解不同HF类型的LSS,包括心力衰竭减少 (HFrEF) 和轻微减少或保留射出分数 (HFmrEF/HFpEF),至关重要.
- 对萨库比特里尔/ 瓦尔萨坦对LSS的影响的研究提供了对治疗有效性和患者报告的结果的见解.
研究的目的
- 在患有HFrEF和HFmrEF/HFpEF的患者中分析EQ-5D-3L水平总分 (LSS).
- 通过PARADIGM-HF和PARAGON-HF试验的数据来评估sacubitril/valsartan对LSS的影响.
- 评估LSS与临床结果之间的关联,以及萨库比特里尔/ 瓦尔萨坦对这些结果的影响.
主要方法
- 通过总结5个领域的分数来计算LSS (范围:5-15).
- 在基线LSS三位体中分析了患者的特征.
- 考克斯模型通过LSS三位数评估了主要终点 (高频率住院或心血管死亡);顺序逻辑回归分析了sacubitril/ valsartan与对比剂的LSS变化.
主要成果
- 较高的基线LSS与年龄较大,女性性别,白人种族,更多的并发症和严重的HF相关.
- 在8个月后,萨库比特里尔/ 瓦尔萨坦治疗导致LSS改善较大,恶化较小 (OR: 1. 16; 95% CI: 1. 08-1. 24).
- 萨库比特里尔/ 瓦尔萨坦降低了所有LSS三位体的初级结果风险,并在8个月后实现LSS预测了后续结果.
结论
- 在HFrEF和HFmrEF/ HFpEF患者中,萨库比特/ 瓦尔萨坦显著改善了健康状况.
- 该药物在减少HF事件和改善患者报告的LSS频谱中的疗效.
- 对于评估治疗效果和预测心力衰竭治疗结果,LSS是一个有价值的工具.
相关概念视频
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

